Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for advanced gastric carcinoma.
|
| Abstract |
To evaluate the activity and safety of a combination chemotherapy with epirubicin, cisplatin, and a protracted venous infusion of 5-fluorouracil (ECF) in unresectable or metastatic gastric cancer, a phase II study was performed. Thirty-five chemotherapy-naive patients were given ECF. Epirubicin (50 mg/m(2) intravenous, i.v.) and cisplatin (60 mg/m(2) i.v.) were administered every three weeks during a continuous intravenous infusion of 5-fluorouracil (250 mg/m(2) /day) using infusion pump. One complete response and 19 partial responses (response rate=62%) were achieved. Eight patients remained stable, whereas in four patients the disease progressed. The median duration of response was 22 weeks (95% confidence interval, 18-27 weeks). The median survival for all patients was 10 months (95% confidence interval, 6-14 months), with a 1-yr survival rate of 40%. A total of 184 cycles of chemotherapy were administered. Grade 3 or 4 emesis occurred in 3%, mucositis in 2%, anemia in 10%, and leukopenia in 3% of the cycles. Central venous catheter complications that required line removal occurred in 37% (n=13) of the patients. No patient died of toxicity. Overall, the ECF regimen showed high anti-tumor activity with a tolerable toxicity pattern.
|
|---|---|
| Authors | Eun Kyung Cho, Woon Ki Lee, Do Yoon Lim, Soo-Mee Bang, Dong Kyun Park, Yeon-Ho Park, Oh Sang Kwon, Duck Joo Choi, Dong Bok Shin, Jae Hoon Lee, Tae Hoon Lee |
| Journal | Journal of Korean medical science (J Korean Med Sci) Vol. 17 Issue 3 Pg. 348-52 (Jun 2002) ISSN: 1011-8934 [Print] Korea (South) |
| PMID | 12068138 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article) |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!